ASN Update - Sparsentan Redefining IgAN Treatment Rare Kidney Disease Show podcast

#Fitness #Podcasting Education #Medicine #Travere Therapeutics #Rare Kidney Disease #RKD #Travers #Igans #Fsgs

39:33

"The basic premise of the event is that hunters hunt rattlesnakes from the surrounding environment all across West Texas, and bring them into the roundup for the weekend. And during the roundup, these snakes are kept in a pit and then, one by one, beheaded and skinned in front of in front of audiences." - Elizabeth MeLampy Elizabeth MeLampy is a lawyer dedicated to animal rights and protection, and her passion for this work shines through in her latest book, Forget the Camel, the Madcap World of Animal Festivals and What They Say About Being Human . To research the book, Elizabeth traveled across the country, immersing herself in a wide range of animal festivals — from the Iditarod dog sled race to the rattlesnake roundup in Sweetwater, Texas. Elizabeth examines these festivals as revealing microcosms of our broader relationship with animals. Whether it's rattlesnake hunts, frog-jumping contests, ostrich races, or groundhog celebrations, these events reflect the ways humans use animals to express cultural identity, community pride, and historical traditions. Yet beneath the pageantry and excitement lies a deeper question: Is our fascination with these spectacles worth the toll it takes on the animals involved? With compassion and insight, Elizabeth invites readers to consider whether there’s a more ethical and empathetic way to honor our stories — one that respects both animals and the traditions they inspire. Please listen, share and read, Forget the Camel. It will be released on April 8th, 2025. https://apollopublishers.com/index.php/forget-the-camel/…

Rare Kidney Disease Show »
ASN Update - Sparsentan Redefining IgAN Treatment

about a year ago 19:07

MP3•Episode home

In this episode of the Rare Kidney Disease Show, a panel of nephrology experts explore the latest data on sparsentan, as presented at ASN Kidney Week 2024.

Dr. Hiddo Heerspink presents a post hoc analysis of the PROTECT trial comprised of patients who achieved complete proteinuria remission.

Dr. Chee Kay Cheung shares interim data from the SPARTAN study on sparsentan therapy in treatment-naïve patients with IgA nephropathy.

Lastly, Dr. Bruce Hendry discusses combination treatment of sparsentan with SGLT2i in the SPARTACUS study.

These discussions are introduced by Dr. Edgar Lerma, who offers his insights into the possible clinical implications of these data.

5 episodes

ASN Update - Sparsentan Redefining IgAN Treatment

Rare Kidney Disease Show

published about a year ago

MP3•Episode home

In this episode of the Rare Kidney Disease Show, a panel of nephrology experts explore the latest data on sparsentan, as presented at ASN Kidney Week 2024.

Dr. Hiddo Heerspink presents a post hoc analysis of the PROTECT trial comprised of patients who achieved complete proteinuria remission.

Dr. Chee Kay Cheung shares interim data from the SPARTAN study on sparsentan therapy in treatment-naïve patients with IgA nephropathy.

Lastly, Dr. Bruce Hendry discusses combination treatment of sparsentan with SGLT2i in the SPARTACUS study.

These discussions are introduced by Dr. Edgar Lerma, who offers his insights into the possible clinical implications of these data.

5 episodes

#Fitness #Podcasting Education #Medicine #Travere Therapeutics #Rare Kidney Disease #RKD #Travers #Igans #Fsgs

All episodes

1
ASN Update - Sparsentan Redefining IgAN Treatment 19:07

10 weeks ago19:07

19:07

In this episode of the Rare Kidney Disease Show, a panel of nephrology experts explore the latest data on sparsentan, as presented at ASN Kidney Week 2024. Dr. Hiddo Heerspink presents a post hoc analysis of the PROTECT trial comprised of patients who achieved complete proteinuria remission. Dr. Chee Kay Cheung shares interim data from the SPARTAN study on sparsentan therapy in treatment-naïve patients with IgA nephropathy. Lastly, Dr. Bruce Hendry discusses combination treatment of sparsentan with SGLT2i in the SPARTACUS study. These discussions are introduced by Dr. Edgar Lerma, who offers his insights into the possible clinical implications of these data.…

1
Rethinking IgAN: A Different Perspective from Community Nephrologists : 4 15:58

32 weeks ago15:58

15:58

Luis Velez, MD is a board-certified community nephrologist in San Antonio, TX with expertise in hypertension and glomerular disorders. Jessica Coleman, MD is a board-certified community nephrologist practicing between Savanah, GA and Charleston, SC with expertise in hypertension and glomerular disorders. In this episode, Drs Velez and Coleman discuss management of IgAN patients from the viewpoint of community nephrologists. They discuss the evolution in their management of IgAN, highlighting the availability of new data such as RaDaR as a key driver of change. With greater awareness of the role of proteinuria, they advocate for early and aggressive treatment to avoid long term complications of IgAN. Key Quotes: “RaDaR taught me that the traditional way of looking at IgA nephropathy is wrong. We realized this is a disease state that absolutely can progress and can progress more rapidly than what we initially appreciated and certainly at a younger age in these patients . (02:25) “When we look at patients with proteinuria, even just 0.5 g/d, a third of patients under 40 are going to progress to end stage kidney disease in ten years [RaDaR].” (04:30) “With the RaDaR data, we see levels of proteinuria 0.5 -0.8 g/d still being significant markers for disease progression.” (08:56) Key Takeaways: IgAN is not a benign disease Proteinuria is the most important prognostic indicator of disease progression in IgA Nephropathy HCPs should be targeting lower proteinuria goals to achieve complete remission <0.3 g/d The updated KDIGO Guidelines should support clinicians’ decisions to target complete remission…

1
The Role of Endothelin in IgAN, ft. Dr. Donald Kohan : 3 17:25

39 weeks ago17:25

17:25

Episode Overview: Donald Kohan, PhD is an Emeritus Professor at the University of Utah Health with expertise in endothelin receptors, sodium transporters, and the renin-angiotensin-aldosterone system in chronic kidney disease. In this episode, Professor Kohan provides an overview of the endothelin system and how it relates to the pathophysiology of chronic kidney disease and IgA nephropathy specifically. Key Quotes: “Endothelin 1 is a really unusual molecule. It's highly stable because it has 2 interchain disulfide bonds that resist degradation. It's extremely potent having about 10 fold higher potency than any other known vasoactive factor.” “Angiotensin and ET-1 cause their effects through different pathways.” “Angiotensin stimulates transient calcium release, which causes more short-term contraction and other effects. While endothelin 1 stimulates more sustained calcium release, which then elicits longer lasting pathophysiologic effects.” Key Takeaways: (04:41) Endothelin-1 acts via ETA receptors to cause vasoconstriction, fibrosis, cell proliferation and other effects that promote chronic kidney disease (06:15) The endothelin and renin-angiotensin systems interact, forming a vicious cycle that worsens kidney injury (12:19) In IgA nephropathy models, combined ETA + angiotensin receptor blockade with sparsentan reduced proteinuria and kidney injury more than angiotensin blockade alone…

1
Unmet Needs in IgAN: Burden of Disease & Long-Term Impact on Patients ft. Dr. Jonathan Barratt : 2 15:44

48 weeks ago15:44

15:44

Overview: In this episode of the Rare Kidney Disease Show, Professor Jonathan Barratt discusses the need to take a long-term approach when managing IgA nephropathy patients. He presents data from the UK National Registry of Rare Kidney Diseases (RaDaR). During this recording you will hear Professor Barratt discussing the continued risk of progression to end stage renal disease even in patients with proteinuria of less than 1g/day, the current threshold of high risk as per KDIGO guidelines. The data from the UK has been reinforced by recent database studies and these will also be discussed by Professor Barratt. Key Quotes: "If you have IgA Nephropathy and you're diagnosed as a child, half of those children have developed kidney failure at 20 years." "We need to be thinking, what is it like for that patient in front of us being 50 or 60, not necessarily what's going to happen in the next five or ten years." "If we don't think the longer term, we're going to under-treat and not serve our patients well." Key Takeaways: IgA nephropathy patients often have decades of life ahead of them, so physicians should focus on minimizing lifetime risk of kidney failure rather than short-term outcomes (00:02:11) RaDaR data shows high rates of kidney failure among IgA nephropathy patients in the UK, even those diagnosed and treated as children (00:04:05) Per the RaDaR publication, an eGFR decline of <1 ml/min per 1.73 m2 per year must be the target if patients are to avoid kidney failure (00:06:48) In the UK, 1 in 4 IgA nephropathy patients with 0.5-1 g/day proteinuria reach ESRD within 10 years (00:08:23) Recent US database searches confirm high rates of CKD progression and kidney failure in IgA nephropathy patients, even those with lower proteinuria levels (00:13:20)…

1
Getting Ahead of IgAN: A New Treatment Paradigm for Disease Control ft. Dr. Brad Rovin : 1 16:15

1 year ago16:15